0 items - $0.00 0
Kanaklyx
0 items - $0.00 0
Kanaklyx
Close
Retatrutide 10 mg COA verified peptide research compound laboratory use only Kanaklyx

Retatrutide

Price range: $85.00 through $233.00

Retatrutide is a research-use-only peptide compound commonly studied in laboratory and clinical-research settings involving multi-receptor incretin pathway analysis, including GIP, GLP-1, and glucagon receptor signaling.

Secure checkout. Available card and bank-payment options are confirmed at checkout.

Add to Wishlist
Add to Wishlist
SKU: KNX-RETA Categories: , Tags: , , Product ID: 624

Research catalog profile

Retatrutide

Retatrutide is a research-use-only peptide compound commonly studied in laboratory and clinical-research settings involving multi-receptor incretin pathway analysis, including GIP, GLP-1, and glucagon receptor signaling.

Catalog reference KNX-RETA
Catalog classification ,
Strength 15mg / 20mg / 30mg / 50mg
Intended context Research use only
Research topics

Use the product selector above to confirm the exact strength and configuration before adding this catalog item to your order.

Quality documentation

Review documentation for Retatrutide

Available laboratory documentation is organized in the Kanaklyx COA library. Before relying on a report, confirm that the compound name, labeled strength, and lot or batch identifier match the product supplied.

Review COA Library

Match these details

  • Compound name
  • Labeled strength
  • Lot or batch identifier
  • Laboratory and report date

Only use documentation that clearly corresponds to the item and batch being reviewed.

Description

Retatrutide is a synthetic peptide composed of 39 amino acids. It is studied for its interaction with multiple receptor pathways, including GLP-1, GIP, and glucagon receptors.

Sources & References

Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial

2023 • PMID: 37366315 • DOI: 10.1056/NEJMoa2301972


View Source →

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

2023 • PMID: 37385280 • DOI: 10.1016/S0140-6736(23)01053-X


View Source →

Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes

2026


View Source →

Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial

2025 • PMID: 40609566 • DOI: 10.1016/S2213-8587(25)00092-0


View Source →

Additional information

Strength

15mg, 20mg, 30mg, 50mg

Related products

Retatrutide 10 mg COA verified peptide research compound laboratory use only Kanaklyx
Retatrutide
$85.00 – $233.00Price range: $85.00 through $233.00